FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Walter Jeske

Research Profile

Chemicals & Drugs

Disorders

Thrombocytopenia

Physiology

Concepts & Ideas

Anatomy

Thrombosis

Living Beings

Procedures

Blood Coagulation Tests

Co-author Network

Publications

TOP 3
Jeanine M Walenga; V Escalante; Jawed Fareed; Debra Hoppensteadt; Walter P Jeske; Mamdouh Bakhos
Thromboelastographic evaluation of blood coagulation in the presence of branded and generic enoxaparins.
Walter P Jeske; Jawed Fareed; Debra A Hoppensteadt; Bruce Lewis; Jeanine M Walenga
Pharmacology of argatroban.
M Margaret Prechel; Walter P Jeske; Jeanine M Walenga
Physiological changes in membrane-expressed platelet factor 4: implications in heparin-induced thrombocytopenia.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Walter Jeske (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: Jeanine M Walenga; V Escalante; Jawed Fareed; Debra Hoppensteadt; Walter P Jeske; Mamdouh Bakhos
Thromboelastographic evaluation of blood coagulation in the presence of branded and generic enoxaparins.
International angiology : a journal of the International Union of Angiology 2012;31(6):517-25.
2010: Walter P Jeske; Jawed Fareed; Debra A Hoppensteadt; Bruce Lewis; Jeanine M Walenga
Pharmacology of argatroban.
Expert review of hematology 2010;3(5):527-39.
2010: M Margaret Prechel; Walter P Jeske; Jeanine M Walenga
Physiological changes in membrane-expressed platelet factor 4: implications in heparin-induced thrombocytopenia.
Thrombosis research 2010;125(4):e143-8.
2010: Margaret Prechel; Walter P Jeske; Jeanine M Walenga
Laboratory methods and management of patients with heparin-induced thrombocytopenia.
Methods in molecular biology (Clifton, N.J.) 2010;663():133-56.
2009: Cafer Adiguzel; Walter P Jeske; Debra Hoppensteadt; Jeanine M Walenga; Vinod Bansal; Jawed Fareed
Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2009;15(2):137-44.
2008: M Clark; Debra Hoppensteadt; Jeanine M Walenga; L Myers; J Cunanan; Walter P Jeske; C Adiguzel; Omer Iqbal; Jawed Fareed
Molecular profiling of heparinase-I resistant glycosaminoglycans in contaminated heparins. Comparative studies with uncontaminated heparin and porcine oversulfated chondroitin sulfate.
International angiology : a journal of the International Union of Angiology 2008;27(5):370-6.
2008: Jawed Fareed; Walter P Jeske; Daniel Fareed; Melaine Clark; Rakesh Wahi; Cafer Adiguzel; Debra Hoppensteadt
Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2008;14(4):385-92.
2008: Jeanine M Walenga; M Margaret Prechel; Walter P Jeske; Debra Hoppensteadt; Jyothi Maddineni; Omer Iqbal; Harry L Messmore; Mamdouh Bakhos
Rivaroxaban--an oral, direct Factor Xa inhibitor--has potential for the management of patients with heparin-induced thrombocytopenia.
British journal of haematology 2008;143(1):92-9.
2008: Brian Untch; Walter P Jeske; Jeffrey Schwartz; Sally Botkin; M Margaret Prechel; Jeanine M Walenga; Mamdouh Bakhos
Inflammatory and hemostatic activation in patients undergoing off-pump coronary artery bypass grafting.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2008;14(2):141-8.
2008: Walter P Jeske; Jeanine M Walenga; Debra A Hoppensteadt; Curtis Vandenberg; Aleah Brubaker; Cafer Adiguzel; Mamdouh Bakhos; Jawed Fareed
Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
Seminars in thrombosis and hemostasis 2008;34(1):74-85.
2007: Dominique Joyal; Ferdinand Leya; Megan Koh; Richard Besinger; Ravi K Ramana; Steven Kahn; Walter P Jeske; Bruce Lewis; Lowell Steen; Ruben Mestril; Dinesh Arab
Troponin I levels in patients with preeclampsia.
The American journal of medicine 2007;120(9):819.e13-4.
2007: Walter P Jeske; Meredith K McDonald; Debra A Hoppensteadt; Elaine C Bau; Aline Mendes; Carl P Dietrich; Jeanine M Walenga; Erwin Coyne
Isolation and characterization of heparin from tuna skins.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2007;13(2):137-45.
2007: Qing Ma; Umberto Cornelli; Israel Hanin; Walter P Jeske; Robert J Linhardt; Jeanine M Walenga; Jawed Fareed; John Lee
Heparin oligosaccharides as potential therapeutic agents in senile dementia.
Current pharmaceutical design 2007;13(15):1607-16.
2007: Qing Ma; Mahmut Tobu; Christopher Schultz; Walter P Jeske; Debra Hoppensteadt; Jeanine M Walenga; Umberto Cornelli; John Lee; Robert J Linhardt; Israel Hanin; Jawed Fareed
Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides.
Thrombosis research 2007;119(5):653-61.
2006: Jyothi Maddineni; Walter P Jeske; Francis Baltasar; Umberto Cornelli; Marco Manoni; Debra A Hoppensteadt; Jawed Fareed
Modulatory effects of Escherichia coli capsular-derived sulfaminoheparosans and heparins on tissue factor-mediated activation of platelets: flow cytometric analysis.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2006;12(3):311-7.
2006: Jyothi Maddineni; Jeanine M Walenga; Walter P Jeske; Debra A Hoppensteadt; Jawed Fareed; Rakesh Wahi; Rodger L Bick
Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2006;12(3):267-76.
2005: M Margaret Prechel; M K McDonald; Walter P Jeske; Harry L Messmore; Jeanine M Walenga
Activation of platelets by heparin-induced thrombocytopenia antibodies in the serotonin release assay is not dependent on the presence of heparin.
Journal of thrombosis and haemostasis : JTH 2005;3(10):2168-75.
2005: Jeanine M Walenga; M Margaret Prechel; Walter P Jeske; Mamdouh Bakhos
Unfractionated heparin compared with low-molecular-weight heparin as related to heparin-induced thrombocytopenia.
Current opinion in pulmonary medicine 2005;11(5):385-91.
2005: Jeanine M Walenga; Walter P Jeske; Jawed Fareed
Short- and long-acting synthetic pentasaccharides as antithrombotic agents.
Expert opinion on investigational drugs 2005;14(7):847-58.
2005: Harry L Messmore; Walter P Jeske; William H Wehrmacher; Erwin Coyne; Sohrab Mobarhan; Leslie Cho; Fred S Leya; John F Moran
Antiplatelet agents: current drugs and future trends.
Hematology/oncology clinics of North America 2005;19(1):87-117, vi.
2005: Jawed Fareed; Wendy Leong; Debra A Hoppensteadt; Walter P Jeske; Jeanine M Walenga; Rodger L Bick
Development of generic low molecular weight heparins: a perspective.
Hematology/oncology clinics of North America 2005;19(1):53-68, v-vi.
2005: Mahmut Tobu; Qing Ma; Omer Iqbal; Christopher Schultz; Walter P Jeske; Debra A Hoppensteadt; Jawed Fareed
Comparative tissue factor pathway inhibitor release potential of heparins.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2005;11(1):37-47.
2004: Jawed Fareed; Wendy L Leong; Debra A Hoppensteadt; Walter P Jeske; Jeanine M Walenga; Rakesh Wahi; Rodger L Bick
Generic low-molecular-weight heparins: some practical considerations.
Seminars in thrombosis and hemostasis 2004;30(6):703-13.
2004: Jawed Fareed; Walter P Jeske
Small-molecule direct antithrombins: argatroban.
Best practice & research. Clinical haematology 2004;17(1):127-38.
2004: Jeanine M Walenga; Walter P Jeske; M Margaret Prechel; Peter Bacher; Mamdouh Bakhos
Decreased prevalence of heparin-induced thrombocytopenia with low-molecular-weight heparin and related drugs.
Seminars in thrombosis and hemostasis 2004;30 Suppl 1():69-80.
2004: Jeanine M Walenga; Walter P Jeske; M Margaret Prechel; Mamdouh Bakhos
Newer insights on the mechanism of heparin-induced thrombocytopenia.
Seminars in thrombosis and hemostasis 2004;30 Suppl 1():57-67.
2004: Walter P Jeske; Jawed Fareed
Pharmacodynamic considerations in the selection of dosage of tinzaparin for various indications: experimental studies in primates.
Seminars in thrombosis and hemostasis 2004;30 Suppl 1():41-7.
2004: Walter P Jeske; Omer Iqbal; Jawed Fareed; Brigitte Kaiser
A survey of venous thrombosis models.
Methods in molecular medicine 2004;93():221-37.
2004: Jeanine M Walenga; Walter P Jeske; Debra Hoppensteadt; Jawed Fareed
Factor Xa inhibitors.
Methods in molecular medicine 2004;93():95-117.
2004: M Margaret Prechel; Walter P Jeske; Jeanine M Walenga
Laboratory methods for heparin-induced thrombocytopenia.
Methods in molecular medicine 2004;93():83-93.
2004: Walter P Jeske; Jeanine M Walenga
Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia.
Methods in molecular medicine 2004;93():61-82.
2003: Jeanine M Walenga; Walter P Jeske; Debra Hoppensteadt; Jawed Fareed
Factor Xa inhibitors: today and beyond.
Current opinion in investigational drugs (London, England : 2000) 2003;4(3):272-81.
2003: Qing Ma; Christopher Schultz; Brian Neville; Walter P Jeske; Debra Hoppensteadt; Umberto Cornelli; John Lee; Stanley Lorens; Israel Hanin; Jawed Fareed
Pharmacodynamics and pharmacokinetics of C3, a heparin-derived oligosaccharide mixture, in non-human primates.
Thrombosis research 2003;112(4):249-55.
2003: Jawed Fareed; Debra Hoppensteadt; Jeanine M Walenga; Omer Iqbal; Qing Ma; Walter P Jeske; Taqdees Sheikh
Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice.
Clinical pharmacokinetics 2003;42(12):1043-57.
2003: Mahmut Tobu; Omer Iqbal; Qing Ma; Christopher Schultz; Walter P Jeske; Debra Hoppensteadt; Bruce Lewis; Daniel Fareed; Jawed Fareed
Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2003;9(1):1-17.
2002: Sarfraz Ahmad; Sylvia Haas; Debra A Hoppensteadt; Helen Lietz; Ulrike Reid; Norbert Bender; Harry L Messmore; Frank Misselwitz; Peter Bacher; Bhavna S Gaikwad; Walter P Jeske; Jeanine M Walenga; Jawed Fareed
Differential effects of clivarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin-platelet factor 4 antibodies.
Thrombosis research 2002;108(1):49-55.
2002: Mahmut Tobu; Omer Iqbal; Debra A Hoppensteadt; Christopher Shultz; Walter P Jeske; Jawed Fareed
Effects of a synthetic factor Xa inhibitor (JTV-803) on various laboratory tests.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2002;8(4):325-36.
2002: Walter P Jeske; Jeanine M Walenga
Antithrombotic drugs for the treatment of heparin-induced thrombocytopenia.
Current opinion in investigational drugs (London, England : 2000) 2002;3(8):1171-80.
2002: Jeanine M Walenga; Walter P Jeske; M Michel Samama; F Xavier Frapaise; Rodger L Bick; Jawed Fareed
Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent.
Expert opinion on investigational drugs 2002;11(3):397-407.
2002: Qing Ma; Bertalan Dudas; Asif Daud; Omer Iqbal; Debra Hoppensteadt; Walter P Jeske; Umberto Cornelli; John Lee; Stanley Lorens; Ronald Mervis; Israel Hanin; Ishan Capila; Robert J Linhardt; Jawed Fareed
Molecular and biochemical profiling of a heparin-derived oligosaccharide, C3.
Thrombosis research 2002;105(4):303-9.
2002: Brian Untch; Sarfraz Ahmad; Walter P Jeske; Harry L Messmore; Debra A Hoppensteadt; Jeanine M Walenga; Helen Lietz; Jawed Fareed
Prevalence, isotype, and functionality of antiheparin-platelet factor 4 antibodies in patients treated with heparin and clinically suspected for heparin-induced thrombocytopenia. The pathogenic role of IgG.
Thrombosis research 2002;105(2):117-23.
2001: Sarfraz Ahmad; Walter P Jeske; Qing Ma; Jeanine M Walenga; Jawed Fareed
Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist.
Thrombosis research 2001;102(2):143-51.
2001: M Wallock; Walter P Jeske; Mamdouh Bakhos; Jeanine M Walenga
Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test.
Perfusion 2001;16(2):147-53.
2001: M K Orcullo Santillan; J Herring; Debra A Hoppensteadt; Walter P Jeske; JM Herbert; Jawed Fareed
The effect of a novel glycoprotein IIb/IIIa antagonist, SR 121566A, on platelet aggregation and activation in rhesus monkeys.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2001;7(1):10-5.
2000: Sarfraz Ahmad; Walter P Jeske; Jeanine M Walenga; A Aldabbagh; Omer Iqbal; Jawed Fareed
Human anti-heparin-platelet factor 4 antibodies are capable of activating primate platelets: towards the development of a HIT model in primates.
Thrombosis research 2000;100(1):47-54.
2000: A Ahsan; Walter P Jeske; H Wolf; Jawed Fareed
Isoamyl nitrite depolymerized heparin as a universal calibrator for heparins and low molecular weight heparins.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2000;6(3):169-74.
1999: Debra A Hoppensteadt; Walter P Jeske; Jeanine M Walenga; K Fu; LH Yang; T S Ing; JM Herbert; Jawed Fareed
Laboratory monitoring of pentasaccharide in a dog model of hemodialysis.
Thrombosis research 1999;96(2):115-24.
1999: Walter P Jeske; A M Jay; S Haas; Jeanine M Walenga
Heparin-induced thrombocytopenic potential of GAG and non-GAG-based antithrombotic agents.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 1999;5 Suppl 1():S56-62.
1999: Jawed Fareed; Jeanine M Walenga; Debra A Hoppensteadt; Walter P Jeske; Sarfraz Ahmad; Helen Lietz; R McKenna; Harry L Messmore; Sylvia Haas
Soluble adhesion molecules in the HIT syndrome: pathophysiologic role and therapeutic modulation.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 1999;5 Suppl 1():S38-44.
1999: Sarfraz Ahmad; Jeanine M Walenga; Walter P Jeske; Giuseppe Cella; Jawed Fareed
Functional heterogeneity of antiheparin-platelet factor 4 antibodies: implications in the pathogenesis of the HIT syndrome.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 1999;5 Suppl 1():S32-7.
1999: Jeanine M Walenga; Walter P Jeske; AR Fasanella; JJ Wood; Sarfraz Ahmad; Mamdouh Bakhos
Laboratory diagnosis of heparin-induced thrombocytopenia.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 1999;5 Suppl 1():S21-7.
1999: Sarfraz Ahmad; Walter P Jeske; Jeanine M Walenga; Debra A Hoppensteadt; JJ Wood; J M Herbert; Harry L Messmore; Jawed Fareed
Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 1999;5(4):259-66.
1999: Sarfraz Ahmad; A Ahsan; M George; Omer Iqbal; Walter P Jeske; R McKenna; Bruce E Lewis; Jeanine M Walenga; Jawed Fareed
Simultaneous monitoring of argatroban and its major metabolite using an HPLC method: potential clinical applications.
Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 1999;5(4):252-8.
1999: Carl P Dietrich; J F Paiva; RA Castro; SF Chavante; Walter P Jeske; J Fareed; P A Gorin; Aline Mendes; Helena B Nader
Structural features and anticoagulant activities of a novel natural low molecular weight heparin from the shrimp Penaeus brasiliensis.
Biochimica et biophysica acta 1999;1428(2-3):273-83.
1999: Walter P Jeske; Jeanine M Walenga; B E Lewis; Jawed Fareed
Pharmacology of argatroban.
Expert opinion on investigational drugs 1999;8(5):625-54.
1999: Walter P Jeske; H Wolf; A Ahsan; Jawed Fareed
Pharmacologic profile of certoparin.
Expert opinion on investigational drugs 1999;8(3):315-27.
1999: Walter P Jeske; Jawed Fareed
In vitro studies on the biochemistry and pharmacology of low molecular weight heparins.
Seminars in thrombosis and hemostasis 1999;25 Suppl 3():27-33.
1999: Jawed Fareed; Debra A Hoppensteadt; Walter P Jeske; Sarfraz Ahmad; Rodger L Bick
Acquired defects of fibrinolysis associated with thrombosis.
Seminars in thrombosis and hemostasis 1999;25(4):367-74.
1999: Jeanine M Walenga; Walter P Jeske; Diane E Wallis; Mamdouh Bakhos; Bruce E Lewis; Ferdinand Leya; Jawed Fareed
Clinical experience with combined treatment of thrombin inhibitors and GPIIb/IIIa inhibitors in patients with HIT.
Seminars in thrombosis and hemostasis 1999;25 Suppl 1():77-81.
1999: Keith F Izban; Helen Lietz; Debra A Hoppensteadt; Walter P Jeske; Jawed Fareed; Mamdouh Bakhos; Jeanine M Walenga
Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia.
Seminars in thrombosis and hemostasis 1999;25 Suppl 1():51-6.
1999: Jeanine M Walenga; Walter P Jeske; AR Fasanella; JJ Wood; Mamdouh Bakhos
Laboratory tests for the diagnosis of heparin-induced thrombocytopenia.
Seminars in thrombosis and hemostasis 1999;25 Suppl 1():43-9.
1999: Jawed Fareed; Jeanine M Walenga; Debra A Hoppensteadt; Walter P Jeske; Helen Lietz; Sarfraz Ahmad; DD Callas; Harry L Messmore; Sylvia Haas
Selectins in the HIT syndrome: pathophysiologic role and therapeutic modulation.
Seminars in thrombosis and hemostasis 1999;25 Suppl 1():37-42.
1999: Jeanine M Walenga; Walter P Jeske; JJ Wood; Sarfraz Ahmad; Bruce E Lewis; Mamdouh Bakhos
Laboratory tests for heparin-induced thrombocytopenia: a multicenter study.
Seminars in hematology 1999;36(1 Suppl 1):22-8.
1998: Jawed Fareed; Walter P Jeske; Debra Hoppensteadt; R Clarizio; Jeanine M Walenga
Low-molecular-weight heparins: pharmacologic profile and product differentiation.
The American journal of cardiology 1998;82(5B):3L-10L.
1998: Jawed Fareed; Debra Hoppensteadt; Walter P Jeske; R Clarizio; Jeanine M Walenga
Low molecular weight heparins: are they different?
The Canadian journal of cardiology 1998;14 Suppl E():28E-34E.
1997: Walter P Jeske; Jeanine M Walenga; E Szatkowski; M Ero; JM Herbert; S Haas; Mamdouh Bakhos
Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets.
Thrombosis research 1997;88(3):271-81.
1997: Debra A Hoppensteadt; Walter P Jeske; Jeanine M Walenga; K Fu; LH Yang; T Ing; JM Herbert; Jawed Fareed
Efficacy of pentasaccharide in a dog model of hemodialysis.
Thrombosis research 1997;88(2):159-70.
1997: Jawed Fareed; Debra Hoppensteadt; Walter P Jeske; R Clarizio; Jeanine M Walenga
Low molecular weight heparins: a developmental perspective.
Expert opinion on investigational drugs 1997;6(6):705-33.
1997: Jeanine M Walenga; Walter P Jeske; L Bara; M M Samama; Jawed Fareed
Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide.
Thrombosis research 1997;86(1):1-36.
1997: Walter P Jeske; Jawed Fareed; V Eschenfelder; Omer Iqbal; Debra Hoppensteadt; A Ahsan
Biochemical and pharmacologic characteristics of Reviparin, a low-molecular-mass heparin.
Seminars in thrombosis and hemostasis 1997;23(2):119-28.
1996: J M Hayes; Walter P Jeske; DD Callas; Omer Iqbal; Jawed Fareed
Comparative intravenous antithrombotic actions of heparin and site directed thrombin inhibitors in a jugular vein clamping model.
Thrombosis research 1996;82(2):187-91.
1996: Debra A Hoppensteadt; Walter P Jeske; Jawed Fareed; Andrew N Nicolaides
Physical and pharmacologic manipulation of the vascular system as measured by the release of TFPI and other mediators of antithrombotic actions.
International angiology : a journal of the International Union of Angiology 1996;15(1):39-46.
1996: Jawed Fareed; Walter P Jeske; V Eschenfelder; Omer Iqbal; Debra Hoppensteadt; A Ahsan
Preclinical studies on a low molecular weight heparin.
Thrombosis research 1996;81(2 Suppl):S1-27.
1996: Jawed Fareed; Walter P Jeske; Debra Hoppensteadt; R Clarizio; Jeanine M Walenga
Are the available low-molecular-weight heparin preparations the same?
Seminars in thrombosis and hemostasis 1996;22 Suppl 1():77-91.
1996: Walter P Jeske; Debra Hoppensteadt; DD Callas; M J Koza; Jawed Fareed
Pharmacological profiling of recombinant tissue factor pathway inhibitor.
Seminars in thrombosis and hemostasis 1996;22(2):213-9.
1995: Walter P Jeske; Debra Hoppensteadt; Jawed Fareed; E Bermes
Measurement of functional and immunologic levels of tissue factor pathway inhibitor. Some methodologic considerations.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1995;6 Suppl 1():S73-80.
1995: Debra A Hoppensteadt; Walter P Jeske; Jawed Fareed; E W Bermes
The role of tissue factor pathway inhibitor in the mediation of the antithrombotic actions of heparin and low-molecular-weight heparin.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1995;6 Suppl 1():S57-64.
1995: A Ahsan; Walter P Jeske; Debra Hoppensteadt; J C Lormeau; H Wolf; Jawed Fareed
Molecular profiling and weight determination of heparins and depolymerized heparins.
Journal of pharmaceutical sciences 1995;84(6):724-7.
1995: Walter P Jeske; Debra Hoppensteadt; R Klauser; A Kammereit; P Eckenberger; S Haas; P Wyld; Jawed Fareed
Effect of repeated Aprosulate and Enoxaparin administration on tissue factor pathway inhibitor antigen levels.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1995;6(2):119-24.
1995: Debra A Hoppensteadt; Jeanine M Walenga; A Fasanella; Walter P Jeske; Jawed Fareed
TFPI antigen levels in normal human volunteers after intravenous and subcutaneous administration of unfractionated heparin and a low molecular weight heparin.
Thrombosis research 1995;77(2):175-85.
1995: Omer Iqbal; Walter P Jeske; Debra Hoppensteadt; M Koza; Jeanine M Walenga; Jawed Fareed; R Moncada
Procoagulant and anticoagulant effects of intravascular contrast media as assessed by thromboelastography.
Seminars in thrombosis and hemostasis 1995;21 Suppl 4():86-90.
1995: Omer Iqbal; Walter P Jeske; Debra Hoppensteadt; Jeanine M Walenga; Jawed Fareed
The approach of thromboelastography in the monitoring of new synthetic antithrombotic agents, GL-522 and GL-2021.
Seminars in thrombosis and hemostasis 1995;21 Suppl 4():72-5.
1995: Jawed Fareed; Walter P Jeske; V Eschenfelder; Omer Iqbal; Debra Hoppensteadt; A Ahsan
Pharmacologic validation of the clinical effects of an optimized low-molecular-weight heparin-reviparin.
Seminars in thrombosis and hemostasis 1995;21(2):212-27.
1995: Walter P Jeske; J C Lormeau; DD Callas; Omer Iqbal; Debra Hoppensteadt; Jawed Fareed
Antithrombin III affinity dependence on the anticoagulant, antiprotease, and tissue factor pathway inhibitor actions of heparins.
Seminars in thrombosis and hemostasis 1995;21(2):193-200.
1994: B Kaiser; Walter P Jeske; Debra Hoppensteadt; Jawed Fareed
Inhibitory effects of TFPI variants on thrombin and factor Xa generation in fibrinogen-deficient human plasma.
Thrombosis research 1994;76(6):561-8.
1994: B Kaiser; Debra A Hoppensteadt; Walter P Jeske; T C Wun; Jawed Fareed
Inhibitory effects of TFPI on thrombin and factor Xa generation in vitro--modulatory action of glycosaminoglycans.
Thrombosis research 1994;75(6):609-16.
1994: R Kijowski; Debra Hoppensteadt; Walter P Jeske; Jawed Fareed
Protamine sulfate neutralization of the anticoagulant activity of Aprosulate, a synthetic sulfated lactobionic acid amide.
Thrombosis research 1994;73(5):349-59.
1994: A Ahsan; Walter P Jeske; J Mardiguian; Jawed Fareed
Feasibility study of heparin mass calibrator as a GPC calibrator for heparins and low molecular weight heparins.
Journal of pharmaceutical sciences 1994;83(2):197-201.
1993: Debra Hoppensteadt; Walter P Jeske; Jawed Fareed
Pharmacological profile of reviparin-sodium.
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 1993;4 Suppl 1():S11-6.
1993: Walter P Jeske; A Ahsan; Jawed Fareed
Molecular weight profiling of low molecular weight heparins utilizing a heparinase degraded oligosaccharide mixture as a calibrator.
Thrombosis research 1993;70(1):39-50.
1993: A Ahsan; Walter P Jeske; Jawed Fareed
Validation of the European Pharmacopeial method for molecular weight profiling of low molecular weight heparins: comparative studies utilizing an improved calibrator, ITH-3.
Seminars in thrombosis and hemostasis 1993;19 Suppl 1():63-8.
1993: Walter P Jeske; B Lojewski; Jeanine M Walenga; Debra Hoppensteadt; A Ahsan; Jawed Fareed
Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarin).
Seminars in thrombosis and hemostasis 1993;19 Suppl 1():229-40.
1993: Omer Iqbal; Walter P Jeske; P Bacher; Debra A Hoppensteadt; Jeanine M Walenga; Jawed Fareed
A comparison of the pharmacokinetic and pharmacodynamic profiles of Clexane and Lovenox in dogs.
Seminars in thrombosis and hemostasis 1993;19 Suppl 1():199-209.
1993: DD Callas; Debra A Hoppensteadt; Walter P Jeske; Omer Iqbal; P Bacher; A Ahsan; Jawed Fareed
Comparative pharmacologic profile of a glycosaminoglycan mixture, Sulodexide, and a chemically modified heparin derivative, Suleparoide.
Seminars in thrombosis and hemostasis 1993;19 Suppl 1():49-57.
1993: Walter P Jeske; Jawed Fareed
Antithrombin III- and heparin cofactor II-mediated anticoagulant and antiprotease actions of heparin and its synthetic analogues.
Seminars in thrombosis and hemostasis 1993;19 Suppl 1():241-7.
1993: Debra A Hoppensteadt; Walter P Jeske; A Ahsan; Jeanine M Walenga; Jawed Fareed
Biochemical and pharmacologic profile of defined molecular weight fractions of heparin.
Seminars in thrombosis and hemostasis 1993;19 Suppl 1():12-9.